- Home
- AUST vs NNVC Comparison
AUST vs NNVC Comparison
Compare AUST & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUST
- NNVC
- Stock Information
- Founded
- AUST 2020
- NNVC 2005
- Country
- AUST Canada
- NNVC United States
- Employees
- AUST N/A
- NNVC N/A
- Industry
- AUST
- NNVC Biotechnology: Pharmaceutical Preparations
- Sector
- AUST
- NNVC Health Care
- Exchange
- AUST Nasdaq
- NNVC Nasdaq
- Market Cap
- AUST 21.5M
- NNVC 22.0M
- IPO Year
- AUST 2022
- NNVC N/A
- Fundamental
- Price
- AUST $1.42
- NNVC $1.50
- Analyst Decision
- AUST
- NNVC Strong Buy
- Analyst Count
- AUST 0
- NNVC 1
- Target Price
- AUST N/A
- NNVC $6.50
- AVG Volume (30 Days)
- AUST 156.5K
- NNVC 323.3K
- Earning Date
- AUST 03-03-2025
- NNVC 02-14-2025
- Dividend Yield
- AUST N/A
- NNVC N/A
- EPS Growth
- AUST N/A
- NNVC N/A
- EPS
- AUST N/A
- NNVC N/A
- Revenue
- AUST N/A
- NNVC N/A
- Revenue This Year
- AUST N/A
- NNVC N/A
- Revenue Next Year
- AUST N/A
- NNVC N/A
- P/E Ratio
- AUST N/A
- NNVC N/A
- Revenue Growth
- AUST N/A
- NNVC N/A
- 52 Week Low
- AUST $0.79
- NNVC $1.03
- 52 Week High
- AUST $3.19
- NNVC $3.59
- Technical
- Relative Strength Index (RSI)
- AUST 49.76
- NNVC 63.26
- Support Level
- AUST $1.45
- NNVC $1.30
- Resistance Level
- AUST $1.80
- NNVC $1.47
- Average True Range (ATR)
- AUST 0.15
- NNVC 0.11
- MACD
- AUST -0.00
- NNVC 0.04
- Stochastic Oscillator
- AUST 25.49
- NNVC 88.37
About AUST Austin Gold Corp.
Austin Gold Corp is a gold exploration and development company focused on gold targets and making district-scale gold discoveries in Nevada. Exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek in Humboldt County, Lone Mountain and Miller in Elko County, and Fourmile Basin in Nye County.
About NNVC NanoViricides Inc.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.